- Select a blog category
This week’s blog is by our colleague, Lee Feander, a Director specialising in Life Science Supply Chain, which recently appeared in Scrip. The blog looks into new distribution models for the life science industry, and the impact that these models may have for both patients and the future of the industry.
In late 2014 we published our report Transforming care at the end-of-life: Dying well matters a subject that I feel passionate about and which I have continued to champion both through my research and also as a non-executive director in a district general hospital. Indeed, in our most recent report Vital Signs: How to deliver better healthcare across Europe, we included as one of the vital signs, palliative and end-of-life care. In this latter report we included a quote from Atul Gawande, “If end-of-life discussions were an experimental drug, the FDA would approve it”.i This week’s blog, by our colleague, Dr Anni Mekhail, recounts a patient story from her time as a resident doctor, and illustrates poignantly how having meaningful conversations with patients can help ease a very difficult time for the patient, their family and medical staff.
Over the past few decades the regulation of the safety of medical devices has remained relatively unchanged. However, today's medical devices are becoming ever more sophisticated and innovative and existing rules have not kept pace with scientific and technical developments. Moreover, the 2011 silicone breast implant scandal and produce recall of the metal-on-metal hip, highlighted serious weaknesses in the current regulatory system and strengthened the case for modernising current rules for medical devices. Following several years of negotiation, new legislation was agreed by all member countries in June 2016 and will become law in late 2019 or early 2020. This week’s blog, by Fiona Maini and Sarah Chan from our Risk and Regulatory practice explores the implications of the legislation for the medical devices industry.
It’s now nearly two years since we published our report Healthcare and Life Sciences Predictions 2020: A bold future? Since then we have had numerous conversations with clients and other stakeholders on our vision of the future. We acknowledged that our view was an optimistic one but also that the technology to delivery these predictions was already available and even being deployed, albeit not at scale. I was fascinated to read a recent article from my colleague and fellow Research Director at the US Center for Health Solutions, Sarah Thomas, on healthcare consumers’ appetite for technology enabled care and her own take on the potential ways of delivering care to people at homes. I therefore thought I would use this week’s blogs to share Sarah’s insights with our readers.
In our recent report Vital Signs: How to deliver better healthcare across Europe, patient engagement and empowerment is included as one of the seven vital signs of a high performing health system.i During my placement with the Deloitte Centre for Health Solutions, I worked on the final stages of this report publication. One of the quotes from the report that resonates most with me is “If patient engagement were a drug it would be the blockbuster drug of the century and malpractice not to use it”.ii Indeed it reminded me of an incident that occurred last year while I was practicing as an adult psychiatrist and psychotherapist in Germany. In sharing this story I hope to demonstrate why patient engagement matters.
I am delighted to use this week’s blog to introduce one of the Centre’s new analysts, Amen Sanghera. During his MSc studies in Nanotechnology and Regenerative Medicine (2013 -14) Amen was fortunate to gain first-hand exposure to the potential that precision medicine (PM) can have for patients. His blog explores this potential and considers the extent to which key stakeholders (payers, providers, physicians and patients) are ready to embrace the move towards precision medicine.
The UK Sepsis Trust and ‘Starfish’ a powerful story of a sepsis survivor: why raising awareness is key to saving 14,000 lives each year
This week I was privileged to attend a reception at Deloitte introducing a new feature film ‘Starfish’i hosted together with the UK Sepsis Trust. The film is based on the experience of Tom Ray who survived sepsis. This week’s blog features an article written by Dr Ron Daniels BEM, CEO of the UK Sepsis Trust and a global expert on sepsis, together with Tom Ray who recounts his first-hand experience of recovering from the devastating consequences of sepsis.
Can partnerships between industry, providers and academia deliver health systems that are fit for the future?
Our recent report, Vital Signs - How to deliver better healthcare across Europe, set out to explore how six European countries – Denmark, France, Germany, Netherlands, Spain and the UK – are tackling the common challenges that they face. We identified that one of the vital signs of a strong health economy is partnership working between healthcare providers, academia and industry. This week’s blog explores what needs to be in place to create effective partnerships and deliver high quality healthcare. The blog first appeared in Scripi and is the second in a series of exclusive columns that Deloitte is providing to Scrip, and which we agreed we would subsequently share with our own readers.
Over the past few weeks the realities of the financial challenges facing the NHS have become increasingly evident. Analysis by the Nuffield Trust estimates that hospitals will have to achieve twice the level of efficiencies achieved in recent years, to have any hope of closing the £22 billion funding gap by 2020. Furthermore, that without extra funding or unprecedented savings and a steep reduction in patient demand, major cuts in services are inevitable. Evidence is already emerging that treatment waiting times are increasing and rationing is becoming more pervasive.i This week’s blog considers one example of this rationing, cataract surgery, the leading case of reversible blindness and visual impairment worldwide. This issue resonates personally with me, as I saw first-hand the distressing impact that this condition can have on a loved one.
In our recent report Vital Signs: How to deliver better healthcare across Europe, one of the vital signs was hospital productivity which highlighted the importance of standardised systems and processes, technology and new ways of working. This week’s blog discusses how one hospital group in the United States (US) standardised its clinical processes across multiple sites to improve efficiency and productivity. This is the second in a series of contributions from Dr Bob, a partner in our health consulting business on secondment from the US who has spent 20 years as a practicing physician in the US, followed by 20 years as a healthcare consultant working with numerous health systems.
This week we’re delighted to feature an article written by our US colleague Terri Cooper, PhD, Principal and the Federal Health Sector Leader, Deloitte Consulting, LLP on a subject that is personal to us all. Most of us will know of someone, a friend, colleague or family member that cancer has impacted. While the Cancer Moonshot is a US led initiative, the outcomes should, in time, benefit us all in our fight against cancer.